"Bifidobakterien enthaltendes Präparat und Verfahren zur Herstellungdesselben" Die Erfindung bezieht sich auf ein Bifidobakterien enthaltendes Präparatzur Substitution gestörter Darmfloren bzw. zur Aufrechterhaltung normaler Floraverhältnissesowie auf ein Verfahren sur Herstellung dieses Präparates."Preparation containing bifidobacteria and process for productionthe same "The invention relates to a preparation containing bifidobacteriato replace disturbed intestinal flora or to maintain normal flora conditionsas well as a process for the production of this preparation.
Es ist bekannt, daß unter der Vielzahl von Mikroorganismen, die denmenschlichen Darmkanal besiedeln, bestimmte Bakteriengruppen, zum Beispiel Colikeimeoder verschiedene Arten von Laktobasillen von besonderer Bedeutung sind.It is known that among the multitude of microorganisms which thecolonize the human intestinal tract, certain groups of bacteria, for example coli germsor different types of lactobasils are of particular importance.
In neuerer Zeit konnte festgestellt werden, daß der menschliche Darmkanalzu etwa 40 % von Keimen der Bifidusgruppe und ru weiteren 40 % von keimen der Bacteroidesgruppebesiedelt ist. Dagegen beträgt der Anteil der aeroben Laktobasillen nur X nl 5 %der Gesamtkeimsahl und die coliformen Keime dürfen im Normalfall eine Gesamtkeimzahlvon rund 1 % nicht übersteigen. Die prozentualen Restanteile entfallen auf zahlreicheandere Keimgruppen (Catenabakterien, Corynebakterion, Streptokokken u.a.), überderen physiologische Bedeutung bis Jetzt nichts bekannt ist.More recently it has been found that the human intestinal canalabout 40% of germs of the bifidus group and another 40% of germs of the Bacteroides groupis populated. In contrast, the proportion of aerobic lactobasils is only X nl 5%the total number of germs and the coliforms may normally have a total number of germsof around 1%. The remaining percentages are attributable to numerousother groups of germs (catenabacteria, corynebacteria, streptococci, etc.), overwhose physiological significance is not yet known.
Alle bisher aufgefundenen Darmkeime, einschließlich der Colibakterien,sind als potentiell pathogene Keime anzusehen, das heißt, sie kannen sowohl im Dannselbst, sofern eine gestörte Darmflora vorliegt, als Krankheitserregerwirksam werden, sie können Jedoch auch außerhalb des Darmes auf Schleihhäuten oderin Wunden, Entzündungen oder Eiterungen hervorrufen.All intestinal germs found so far, including coli bacteria,are to be regarded as potentially pathogenic germs, that is, they can both in the theneven if a disturbed oneIntestinal flora is present as a pathogenThey can be effective, however, also outside of the intestine on coarse membranes orcause inflammation or suppuration in wounds.
Die einzige, bisher bekannte Ausnahme in dieser Beziehung bilden dieKeime der Bifidusgruppe. Diese sind von allen bisher im Darm aufgefundenen Mikroorganismendie einzigen wirklich apathogenen Keime. Vermutlich ist die Aufrechterhaltung normalerFloraverhältnisse in erster Linie dieser Kelingruppe zuzuschreiben. So ist es bekannt,daß mit Muttermilch ernährte Säuglinge eine praktisch reine Bifidusflora in ihremDarm beherbergen und daß das Gedeihen dieser Säuglinge in einem direkten Zusammenhangmit dieser Bifidusflora steht.The only known exception in this respect are theGerms of the bifidus group. These are from all microorganisms previously found in the intestinethe only really non-pathogenic germs. Presumably maintenance is more normalFlora conditions can be attributed primarily to this kelo group. So it is knownthat breast-fed infants have practically pure bifidus flora in theirsGut accommodate and that the thriving of these infants is directly relatedwith this bifidus flora.
Bifidobakterien richten durch ihr starkes Säuerungsvermögen in denoberen Darmabschnitten eine "Säureschranke" auf, welche es den in den tieferen Darmabschnittensiedelnden Fäulniserregern verwehrt, in höhere Darmabschnitte aufzusteigen, wo siepathogen wirksam werden könnten.Bifidobacteria direct due to their strong acidity in theupper intestinal sections create an "acid barrier", which is present in the deeper intestinal sectionscolonizing putrefactive pathogens are prevented from ascending into higher intestinal sections, where theycould be pathogenic.
Bifidobakterien bilden eine antibiotisch wirksame Substanz, die sichgegen gramnegative und auch gegen gewisse grampositive Keime richtet.Bifidobacteria form a substance that has an antibiotic effectdirected against gram-negative and also against certain gram-positive germs.
Es ist schon versucht worden, die gestörten Darmflorcn (z.B.Attempts have already been made to remove the disturbed intestinal flora (e.g.
nach antibiotiabher Behandlung) dadurch wieder zu normalisieren, daßman lebende Bifiduskeime in entsprechend großer Menge suführte, in der Hoffnung,daß eine Ansiedelung dieser Keime im Darmtrakt möglich sei. Es hat sich Jedoch erwiesen,daß diese Bifiduskeime war als sogenaante passagere Keime den Darmtrakt durchwandernund in der Fäkalflora wiedersufinden sind, daß aber eine echte Ansiedelung dieserKeime nur in sehr wenigen Fällen gelingt. In der Regel verschwanden auch die inder Fähalflora nachweisbaren zugeführten Biiiduskeime bald nach dem Absetzen derentsprechenden Präparate.after antibiotic treatment) to normalize again thatliving bifidus germs were fed in correspondingly large quantities, in the hope thatthat a settlement of these germs in the intestinal tract is possible. However, it has been shownthat these bifidus germs were passing through the intestinal tract as so-called transient germsand are found again in the faecal flora, but that there is a real settlement of theseGerms only succeed in very few cases. Usually the inthe fähalflora detectable supplied Biiidus germs soon after the weaningcorresponding preparations.
Aufgabe der Erfindung irt es, ein Präparat zu schaffen, welches zurBehandlung sogenannter dysbiotischer Darmflorengeeignet ist undanhaltende Ansiedelung bzw. Neuanziedelung von humanen Btfidusarten im Darmtraktbewirkt.The object of the invention irt it to create a preparation which forTreatment of so-called dysbiotic intestinal florais suitable andsustained settlement or new settlement of human Btfidus species in the intestinal tractcauses.
Es wurde festgestellt, daß die Bifidusflora Jeder Person sehr heterogenzusammengesetzt ist. Von den derzeit bekannten, rund 15 verschiedenen Arten vonBifidobakterien beherbergt Jeder Mensch in seinem Intestinaltrakt mehrere, oft biszu 7 verschiedene Arten. Es hat sich als praktisch unmöglich erwiesen, eine andereBifidusart als die bereits im Darmkanal vorhandenen Arten, anzusiedeln. Es ist Jedochdurchaus eine Ansiedelung einer oder mehrerer Arten möglich, die bei einer bestimmtenPerson bereits vorhanden sind, wenn auch (etwa durch antibiotische Schädigung) nurnoch in sehr geringer und für die Aufrechterhaltung normaler Floraverhältnisse ungenügenderAnzahl.It was found that the bifidus flora of every person is very heterogeneousis composed. Of the currently known, around 15 different types ofEvery person harbors several, often up to, bifidobacteria in their intestinal tractto 7 different types. It has proven practically impossible any otherBifidus species than the species already present in the intestinal canal. However, it isA settlement of one or more species is quite possible, with a certainPerson already exist, even if only (e.g. due to antibiotic damage)still very little and inadequate for the maintenance of normal flora conditionsNumber.
Die bisher zur Behandlung von florabedingten Darmstörungen angewandtenPräparate enthielten lediglich eine einzig.The previously used for the treatment of flora-related intestinal disordersPreparations contained only one.
Bifidusart. Es ist daher erklärlich, daß anhaltende therapeutischeErfolge mit solchen Präparaten nur bei Personen erreicht werden konnten, die ebendiese eine Art in ihrem Darm beherbergten.Bifidus species. It is therefore understandable that persistent therapeuticSuccesses with such preparations could only be achieved with people whoharbored this one species in their intestines.
Die vorstehend erläuterte Aufgabe wird dadurch gelöst, daß das erfindungsgemäßePräparat mehrere Arten der Gattung Bifidobakterien als Mischung enthält.The object explained above is achieved in that the inventivePreparation containing several species of the genus Bifidobacteria as a mixture.
Die Mischung kann in frischer Form verwendet werden, sie kann jedochauch schonend getroclnet sein.The mixture can be used fresh, but it canalso be gently dried.
Weiterhin kann die Mischung zusätzliche essentielle Keime der Darmflorasowie ein optimales Nährsubstrat enthalten.Furthermore, the mixture can contain additional essential germs of the intestinal floraas well as an optimal nutrient substrate.
Als NJhrsubstrat eignet sich Milch oder Molke, die mit einem Zusatzvon Wachstumsaktivatoren versehen sein kann. Diese Wachstumsaktivatoren können Hefeextrakteoder Hefeautolysate sein.Milk or whey with an additive is suitable as a nutrient substratecan be provided by growth activators. These growth activators can be yeast extractsor yeast autolysates.
Das erfindungsgemäße Präparat kann dadurch hergestellt werden, daßmehrere Arten der Gattung Bitidobakterien als Reinkulturen für sich kultiviert unddann miteinander vermischt werden.The preparation according to the invention can be produced in thatseveral species of the genus Bitidobacteria cultivated as pure cultures for themselves andthen mixed together.
Die Mischung kann schonend getrocknet werden. Es können der Mischungauch andere exxentielle Keime der Darmflora ebenso wie ein optimales Nährsubstratzugesetzt werden.The mixture can be gently dried. It can mixalso other exxential germs of the intestinal flora as well as an optimal nutrient substratecan be added.
Die Keime der Darmflore können vor der Vermischung mit den verschiedenenStämmen der 3ifidobakterien in dem Nährsubstrat selbst kultiviert werden. Als Nhhrsubstratkann Milch oder Molke verwendet werden, der Wachstumsaktivatoren zugesetzt seinkönnen. Als Wachstumsaktivatoren eignen sich z.B, Hefeextrakte oder Hefeautolysate.The germs of the intestinal flora can prevent mixing with the variousStrains of the 3ifidobacteria are cultivated in the nutrient substrate itself. As a sewing substratemilk or whey can be used to which growth activators have been addedcan. Examples of suitable growth activators are yeast extracts or yeast autolysates.
Die Erfindung wird nachfolgend anhand von zwei Beispielen erläutert:Beispiel 11 Reinkulturen von Bifidobakterien, die t.B.The invention is explained below using two examples:Example 11 Pure cultures of bifidobacteria produced by t.B.
nach dem deutschen Patent 19 46 661 gewonnen wurden, werden in Milchmit einem Zusatz von Hefeextrakt oder Hefeautolysat weitergesüchtet, durch dieseWeiterzüchtung aui ein beliebig großes Volumen vermehrt, sodann miteinander im gleichenVerhältnis, bezogen auf die Keimzahlen der Kulturen, vermischt. Dieses Gemisch eignetsich in frischer oder schonend getrockneter Form zur Behandlung gestörter Darmfloren. according to the German patent 19 46 661 are obtained in milkwith the addition of yeast extract or yeast autolysate are further addicted by thisFurther breeding increased to an arbitrarily large volume, then with one another in the same wayRatio, based on the number of germs in the cultures, mixed. This mixture is suitablein fresh or gently dried form for the treatment of disturbed intestinal flora.
Beispiel 2) Reinkulturen von Bifidobakterien werden miteinander vermischtwie nach Beispiel 1. Nach der Vermischung dieser Kulturen miteinander kann dieseMischkultur entweder allein oder in Verbindung mit anderen Milchsäurebildern surHerstellung von Milcherzeugnissen verwendet werden, die dann den gleichen Zweckendienen können wie das nach Beispiel 1 gewonnene Präparat.Example 2) Pure cultures of bifidobacteria are mixed with one anotheras in Example 1. After these cultures have been mixed with one another, this canMixed culture either alone or in conjunction with other lactic acid images surManufacture of dairy products are used, which then serve the same purposescan serve like the preparation obtained according to Example 1.
Das im Rahmen der Erfindung vorgesehene gleichzeitige Verabreichenvon Bifidobakterien und einem für diese Keime optimalen Nährsubstrat schafft günstigeLebensbedingungen im Darmkanal, die für die erfolgreiche Ansiedelung der Bifidobakteriensehr förderlich ist.The simultaneous administration provided within the scope of the inventionof bifidobacteria and an optimal nutrient substrate for these germs creates favorableLiving conditions in the intestinal tract that are necessary for the successful settlement of the bifidobacteriais very beneficial.
P a t e n t a n s p r ü c h e P a t e n t a n s p r ü c h e
| Application Number | Priority Date | Filing Date | Title | 
|---|---|---|---|
| DE2134179ADE2134179A1 (en) | 1971-07-09 | 1971-07-09 | Prepns contg several bifidobacterium species - for normalizing intestinal flora | 
| Application Number | Priority Date | Filing Date | Title | 
|---|---|---|---|
| DE2134179ADE2134179A1 (en) | 1971-07-09 | 1971-07-09 | Prepns contg several bifidobacterium species - for normalizing intestinal flora | 
| Publication Number | Publication Date | 
|---|---|
| DE2134179A1true DE2134179A1 (en) | 1973-01-25 | 
| Application Number | Title | Priority Date | Filing Date | 
|---|---|---|---|
| DE2134179APendingDE2134179A1 (en) | 1971-07-09 | 1971-07-09 | Prepns contg several bifidobacterium species - for normalizing intestinal flora | 
| Country | Link | 
|---|---|
| DE (1) | DE2134179A1 (en) | 
| Publication number | Priority date | Publication date | Assignee | Title | 
|---|---|---|---|---|
| DE2813733A1 (en)* | 1977-03-31 | 1978-10-12 | Yakult Honsha Kk | PROCESS FOR THE MANUFACTURING OF FOOD AND BEVERAGES CONTAINING BIFIDOBACTERIA | 
| US4335107A (en)* | 1978-06-05 | 1982-06-15 | Snoeyenbos Glenn H | Mixture to protect poultry from salmonella | 
| DE3125797A1 (en)* | 1981-06-30 | 1983-01-13 | Rudolf Dr. Schuler | Dietetic agent | 
| FR2560046A1 (en)* | 1984-02-24 | 1985-08-30 | Schuler Rudolf | Dietetic product contg. bifidobacterium suis or infantis | 
| EP0181170A3 (en)* | 1984-11-05 | 1988-03-16 | Kabushiki Kaisya Advance Kaihatsu Kenkyujo | Hypocholesterolemically active products | 
| WO1990001335A1 (en)* | 1988-08-02 | 1990-02-22 | Borody Thomas J | Treatment of gastro-intestinal disorders | 
| EP0482530A3 (en)* | 1990-10-25 | 1993-03-31 | Karl Heinz Hoelzel | Composition for the regulation of intestinal flora | 
| US5443826A (en)* | 1988-08-02 | 1995-08-22 | Borody; Thomas J. | Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli | 
| US9320763B2 (en) | 2000-07-25 | 2016-04-26 | Thomas Julius Borody | Probiotic recolonisation therapy | 
| US9649343B2 (en) | 2011-03-09 | 2017-05-16 | National Institutes of Health (NIH); U.S. Department of Health and Human Services (DHHS); The United States of America, NIH Division of Extramural Inventions and Tehnology Resources (DEITR) | Compositions and methods for transplantation of colon microbiota | 
| US9901603B2 (en) | 2015-05-14 | 2018-02-27 | Crestovo Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and device for delivering them | 
| US9962413B2 (en) | 2010-08-04 | 2018-05-08 | Crestovo Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them | 
| US10092601B2 (en) | 2016-10-11 | 2018-10-09 | Crestovo Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders | 
| US10195235B2 (en) | 2016-08-03 | 2019-02-05 | Crestovo Holdings Llc | Methods for treating ulcerative colitis | 
| US11026978B2 (en) | 2016-10-11 | 2021-06-08 | Finch Therapeutics Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders | 
| US11040073B2 (en) | 2017-04-05 | 2021-06-22 | Finch Therapeutics Holdings Llc | Compositions and methods for treating diverticulitis and related disorders | 
| US11166990B2 (en) | 2018-07-13 | 2021-11-09 | Finch Therapeutics Holdings Llc | Methods and compositions for treating ulcerative colitis | 
| US11202808B2 (en) | 2015-05-22 | 2021-12-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods for treating autism spectrum disorder and associated symptoms | 
| US11213549B2 (en) | 2016-10-11 | 2022-01-04 | Finch Therapeutics Holdings Llc | Compositions and method for treating primary sclerosing cholangitis and related disorders | 
| US11357801B2 (en) | 2016-06-15 | 2022-06-14 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods for treating autism spectrum disorder and associated symptoms | 
| US11433102B2 (en) | 2017-04-05 | 2022-09-06 | Finch Therapeutics Holdings Llc | Compositions and methods for treating Parkinson's disease (PD) and related disorders | 
| US11542560B2 (en) | 2012-05-25 | 2023-01-03 | Board of Regents on Behalf of Arizona State University | Microbiome markers and therapies for autism spectrum disorders | 
| US11819523B2 (en) | 2016-07-01 | 2023-11-21 | Regents Of The University Of Minnesota | Compositions and methods for C. difficile treatment | 
| US11865145B2 (en) | 2017-08-07 | 2024-01-09 | Finch Therapeutics Holdings Llc | Compositions and methods for maintaining and restoring a healthy gut barrier | 
| US11890306B2 (en) | 2017-05-26 | 2024-02-06 | Finch Therapeutics Holdings Llc | Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same | 
| US11911419B2 (en) | 2018-09-27 | 2024-02-27 | Finch Therapeutics Holdings Llc | Compositions and methods for treating epilepsy and related disorders | 
| US12290538B2 (en) | 2019-07-19 | 2025-05-06 | Finch Therapeutics Holdings Llc | Methods and products for treatment of gastrointestinal disorders | 
| Publication number | Priority date | Publication date | Assignee | Title | 
|---|---|---|---|---|
| DE2813733A1 (en)* | 1977-03-31 | 1978-10-12 | Yakult Honsha Kk | PROCESS FOR THE MANUFACTURING OF FOOD AND BEVERAGES CONTAINING BIFIDOBACTERIA | 
| US4335107A (en)* | 1978-06-05 | 1982-06-15 | Snoeyenbos Glenn H | Mixture to protect poultry from salmonella | 
| DE3125797A1 (en)* | 1981-06-30 | 1983-01-13 | Rudolf Dr. Schuler | Dietetic agent | 
| FR2560046A1 (en)* | 1984-02-24 | 1985-08-30 | Schuler Rudolf | Dietetic product contg. bifidobacterium suis or infantis | 
| EP0181170A3 (en)* | 1984-11-05 | 1988-03-16 | Kabushiki Kaisya Advance Kaihatsu Kenkyujo | Hypocholesterolemically active products | 
| WO1990001335A1 (en)* | 1988-08-02 | 1990-02-22 | Borody Thomas J | Treatment of gastro-intestinal disorders | 
| US5443826A (en)* | 1988-08-02 | 1995-08-22 | Borody; Thomas J. | Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli | 
| US6645530B1 (en) | 1988-08-02 | 2003-11-11 | Gastro Services Pty Limited | Treatment of gastro-intestinal disorders | 
| EP0482530A3 (en)* | 1990-10-25 | 1993-03-31 | Karl Heinz Hoelzel | Composition for the regulation of intestinal flora | 
| US9623056B2 (en) | 2000-07-20 | 2017-04-18 | Crestovo Llc | Probiotic recolonisation therapy | 
| US9572841B2 (en) | 2000-07-25 | 2017-02-21 | Crestovo Llc | Probiotic recolonisation therapy | 
| US9682108B2 (en) | 2000-07-25 | 2017-06-20 | Crestovo Llc | Probiotic recolonisation therapy | 
| US10369175B2 (en) | 2000-07-25 | 2019-08-06 | Crestovo Holdings Llc | Probiotic recolonisation therapy | 
| US9572842B2 (en) | 2000-07-25 | 2017-02-21 | Crestovo Llc | Probiotic recolonisation therapy | 
| US9610308B2 (en) | 2000-07-25 | 2017-04-04 | Crestovo Llc | Probiotic recolonisation therapy | 
| US9408872B2 (en) | 2000-07-25 | 2016-08-09 | Crestovo Llc | Probiotic recolonisation therapy | 
| US10772919B2 (en) | 2000-07-25 | 2020-09-15 | Crestovo Holdings Llc | Probiotic recolonisation therapy | 
| US9468658B2 (en) | 2000-07-25 | 2016-10-18 | Crestovo Llc | Probiotic recolonisation therapy | 
| US9737574B2 (en) | 2000-07-25 | 2017-08-22 | Crestovo Llc | Probiotic recolonisation therapy | 
| US9789140B2 (en) | 2000-07-25 | 2017-10-17 | Crestovo Holdings Llc | Probiotic recolonisation therapy | 
| US9867858B2 (en) | 2000-07-25 | 2018-01-16 | Crestovo Holdings Llc | Probiotic recolonisation therapy | 
| US9320763B2 (en) | 2000-07-25 | 2016-04-26 | Thomas Julius Borody | Probiotic recolonisation therapy | 
| US9901604B2 (en) | 2000-07-25 | 2018-02-27 | Crestovo Holdings Llc | Probiotic recolonisation therapy | 
| US9962414B2 (en) | 2000-07-25 | 2018-05-08 | Crestovo Holdings Llc | Probiotic recolonisation therapy | 
| US10617724B2 (en) | 2010-08-04 | 2020-04-14 | Crestovo Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them | 
| US11065284B2 (en) | 2010-08-04 | 2021-07-20 | Finch Therapeutics Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them | 
| US10022406B2 (en) | 2010-08-04 | 2018-07-17 | Crestovo Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them | 
| US11491193B2 (en) | 2010-08-04 | 2022-11-08 | Finch Therapeutics Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them | 
| US10064899B1 (en) | 2010-08-04 | 2018-09-04 | Crestovo Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them | 
| US11173183B2 (en) | 2010-08-04 | 2021-11-16 | Finch Therapeutics Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them | 
| US11504403B2 (en) | 2010-08-04 | 2022-11-22 | Finch Therapeutics Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them | 
| US11129859B2 (en) | 2010-08-04 | 2021-09-28 | Finch Therapeutics Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them | 
| US10278997B2 (en) | 2010-08-04 | 2019-05-07 | Crestovo Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them | 
| US11541080B2 (en) | 2010-08-04 | 2023-01-03 | Finch Therapeutics Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them | 
| US11103541B2 (en) | 2010-08-04 | 2021-08-31 | Finch Therapeutics Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them | 
| US10328107B2 (en) | 2010-08-04 | 2019-06-25 | Crestovo Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them | 
| US9962413B2 (en) | 2010-08-04 | 2018-05-08 | Crestovo Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them | 
| US10463702B2 (en) | 2010-08-04 | 2019-11-05 | Crestovo Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them | 
| US11890308B2 (en) | 2010-08-04 | 2024-02-06 | Finch Therapeutics Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them | 
| US10610551B2 (en) | 2010-08-04 | 2020-04-07 | Crestovo Holdings, Inc. | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them | 
| US11207356B2 (en) | 2010-08-04 | 2021-12-28 | Finch Therapeutics Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them | 
| US10675309B2 (en) | 2010-08-04 | 2020-06-09 | Crestovo Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them | 
| US11850269B2 (en) | 2010-08-04 | 2023-12-26 | Finch Therapeutics Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them | 
| US11890307B2 (en) | 2010-08-04 | 2024-02-06 | Finch Therapeutics Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them | 
| US10849937B2 (en) | 2010-08-04 | 2020-12-01 | Crestovo Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them | 
| US10857188B2 (en) | 2010-08-04 | 2020-12-08 | Crestovo Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them | 
| US10987385B2 (en) | 2010-08-04 | 2021-04-27 | Finch Therapeutics Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them | 
| US9649343B2 (en) | 2011-03-09 | 2017-05-16 | National Institutes of Health (NIH); U.S. Department of Health and Human Services (DHHS); The United States of America, NIH Division of Extramural Inventions and Tehnology Resources (DEITR) | Compositions and methods for transplantation of colon microbiota | 
| US11801269B2 (en) | 2011-03-09 | 2023-10-31 | Regents Of The University Of Minnesota | Compositions and methods for transplantation of colon microbiota | 
| US9968638B2 (en) | 2011-03-09 | 2018-05-15 | Regents Of The University Of Minnesota | Compositions and methods for transplantation of colon microbiota | 
| US10286012B2 (en) | 2011-03-09 | 2019-05-14 | Regents Of The University Of Minnesota | Compositions and methods for transplantation of colon microbiota | 
| US10286011B2 (en) | 2011-03-09 | 2019-05-14 | Regents Of The University Of Minnesota | Compositions and methods for transplantation of colon microbiota | 
| US10251914B2 (en) | 2011-03-09 | 2019-04-09 | Regents Of The University Of Minnesota | Compositions and methods for transplantation of colon microbiota | 
| US12295974B2 (en) | 2011-03-09 | 2025-05-13 | Regents Of The University Of Minnesota | Compositions and methods for transplantation of colon microbiota | 
| US10028980B2 (en) | 2011-03-09 | 2018-07-24 | Regents Of The University Of Minnesota | Compositions and methods for transplantation of colon microbiota | 
| US11542560B2 (en) | 2012-05-25 | 2023-01-03 | Board of Regents on Behalf of Arizona State University | Microbiome markers and therapies for autism spectrum disorders | 
| US12084727B2 (en) | 2012-05-25 | 2024-09-10 | Arizona Board Of Regents On Behalf Of Arizona State University | Microbiome markers and therapies for autism spectrum disorders | 
| US9901603B2 (en) | 2015-05-14 | 2018-02-27 | Crestovo Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and device for delivering them | 
| US11123377B2 (en) | 2015-05-14 | 2021-09-21 | Finch Therapeutics Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and device for delivering them | 
| US10821138B2 (en) | 2015-05-14 | 2020-11-03 | Crestovo Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and device for delivering them | 
| US12161678B2 (en) | 2015-05-14 | 2024-12-10 | Finch Therapeutics Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and device for delivering them | 
| US11202808B2 (en) | 2015-05-22 | 2021-12-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods for treating autism spectrum disorder and associated symptoms | 
| US11357801B2 (en) | 2016-06-15 | 2022-06-14 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods for treating autism spectrum disorder and associated symptoms | 
| US12186349B2 (en) | 2016-07-01 | 2025-01-07 | Regents Of The University Of Minnesota | Compositions and methods for C. difficile treatment | 
| US11819523B2 (en) | 2016-07-01 | 2023-11-21 | Regents Of The University Of Minnesota | Compositions and methods for C. difficile treatment | 
| US10561690B2 (en) | 2016-08-03 | 2020-02-18 | Crestovo Holdings Llc | Methods for treating ulcerative colitis | 
| US11071759B2 (en) | 2016-08-03 | 2021-07-27 | Finch Therapeutics Holdings Llc | Methods for treating ulcerative colitis | 
| US12390496B2 (en) | 2016-08-03 | 2025-08-19 | Finch Therapeutics Holdings Llc | Methods for treating ulcerative colitis | 
| US10195235B2 (en) | 2016-08-03 | 2019-02-05 | Crestovo Holdings Llc | Methods for treating ulcerative colitis | 
| US10092601B2 (en) | 2016-10-11 | 2018-10-09 | Crestovo Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders | 
| US11213549B2 (en) | 2016-10-11 | 2022-01-04 | Finch Therapeutics Holdings Llc | Compositions and method for treating primary sclerosing cholangitis and related disorders | 
| US11026978B2 (en) | 2016-10-11 | 2021-06-08 | Finch Therapeutics Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders | 
| US11529375B2 (en) | 2017-04-05 | 2022-12-20 | Finch Therapeutics Holdings Llc | Compositions and methods for treating diverticulitis and related disorders | 
| US11040073B2 (en) | 2017-04-05 | 2021-06-22 | Finch Therapeutics Holdings Llc | Compositions and methods for treating diverticulitis and related disorders | 
| US11433102B2 (en) | 2017-04-05 | 2022-09-06 | Finch Therapeutics Holdings Llc | Compositions and methods for treating Parkinson's disease (PD) and related disorders | 
| US11890306B2 (en) | 2017-05-26 | 2024-02-06 | Finch Therapeutics Holdings Llc | Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same | 
| US11865145B2 (en) | 2017-08-07 | 2024-01-09 | Finch Therapeutics Holdings Llc | Compositions and methods for maintaining and restoring a healthy gut barrier | 
| US12285447B2 (en) | 2018-07-13 | 2025-04-29 | Finch Therapeutics Holdings Llc | Methods and compositions for treating ulcerative colitis | 
| US11166990B2 (en) | 2018-07-13 | 2021-11-09 | Finch Therapeutics Holdings Llc | Methods and compositions for treating ulcerative colitis | 
| US11911419B2 (en) | 2018-09-27 | 2024-02-27 | Finch Therapeutics Holdings Llc | Compositions and methods for treating epilepsy and related disorders | 
| US12290538B2 (en) | 2019-07-19 | 2025-05-06 | Finch Therapeutics Holdings Llc | Methods and products for treatment of gastrointestinal disorders | 
| Publication | Publication Date | Title | 
|---|---|---|
| DE2134179A1 (en) | Prepns contg several bifidobacterium species - for normalizing intestinal flora | |
| DE69108846T2 (en) | Whole foods made from hydrolyzed soluble fiber. | |
| DE69227329T2 (en) | Milk bacteria | |
| CH638660A5 (en) | METHOD FOR THE PRODUCTION OF FOODS AND BEVERAGES CONTAINING BIFIDOBACTERIES. | |
| DE2250993C2 (en) | Antibacterial agent | |
| CH642517A5 (en) | METHOD FOR THE PRODUCTION OF FOODS AND BEVERAGES CONTAINING BIFIDOBACTERIES. | |
| CH665126A5 (en) | DIETETARY AGENT FOR REDUCING THE UREA CONCENTRATION IN BODY LIQUIDS AND ITS PRODUCTION. | |
| CH627348A5 (en) | METHOD FOR THE PRODUCTION OF FERMENTED MILK CONTAINING VIVIDABLE BIFIDOBACTERIES AND USE OF THE MILK SO OBTAINED. | |
| DE3120505C2 (en) | Process for the production of solid sour milk products | |
| DE69122186T2 (en) | LACTOBACILLUS ACIDOPHILUS-F-133, PRODUCTION OF LACTIC ACID BACTERIA THEREOF AND METHOD FOR THE PRODUCTION THEREOF | |
| DE69002024T2 (en) | Bioactive lactoferrin derivatives. | |
| CH650645A5 (en) | DIET TABLE. | |
| CH647945A5 (en) | Lyophilised, enzymatically degraded sour milk product | |
| DE2931082C2 (en) | ||
| DE1692313A1 (en) | Process for making dairy products | |
| DE1492779C3 (en) | Process for the manufacture of sour milk products | |
| EP0344786B1 (en) | Inhibiting agent for clostridia | |
| EP0184121B1 (en) | Saccharose-containing, orally administered, foodstuffs, beverages, delicacies and pharmaceutical preparations | |
| DE1019896B (en) | Process for the production of milk products, such as sour milk or the like, with the addition of bacteria | |
| DE2421066A1 (en) | Bifido bacterial preparations - additionally contg. Lactobacillus casei var. rhamnosus | |
| DE2106154A1 (en) | Antibiotic - resistans streptococcus faecalis - for treatment and prophylaxis of digestive disturbances | |
| DE3147311C2 (en) | ||
| EP0515721A1 (en) | Method for producing vegetable foodstuff with low nitrate content | |
| DE2057906A1 (en) | Preacidulated milk for infants - without the risk of acidosis | |
| DE859194C (en) | Process for the cultivation of bacterial strains producing streptomycin |